WASF3 and neoplasm: While every mouse in every group developed tumors (100% tumor incidence) after a ∼4-week latency, tumor burden, as assessed by tumor volume (Fig. 3a) and weight (Fig. 3b), was significantly lower (p < 0.05) in the mice implanted with the WAVE3-deficient cells and the WAVE3-deficient re-expressing phospho-mutant WAVE3.